The content on this site is intended for healthcare professionals only
Cancer patient symptom and physical function reporting by caregivers used as pre...
Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, ...
21 Jun 2022
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
21 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
14 Jun 2022
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy i...
Prof Barbara Eichhorst - University of Cologne, Cologne, Germany
13 Jun 2022
Quizartinib advances overall survival in acute myeloid leukaemia patients
Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA
13 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
9 Jun 2022
ASCO 2022: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
6 Jun 2022
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...
Dr Julie Gralow- Chief Medical Officer, ASCO
5 Jun 2022
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for...
Dr Martin McCabe- University of Manchester, Manchester, England
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
5 Jun 2022